Abiopharma

🔍 Decheng Capital China Life Sciences USD Fund III, L.P. (Executive)

Company: BeyondSpring Inc. (BYSI)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Sold 800 shares of Ordinary Shares at $1.74 per share (Direct)
  Date: 2025-08-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,908,825.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,800 shares of Ordinary Shares at $1.78 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,906,025.00 | transaction_form_type: 4 | Footnotes: F3, F2
• Sold 1,270 shares of Ordinary Shares at $1.81 per share (Direct)
  Date: 2025-09-03 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,904,755.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2025-08-29 | Code: H | nature_of_ownership: By Decheng Capital China Life Sciences USD Fund II, L.P. | shares_owned_after: 1,617,409.00 | Footnotes: F5
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2025-08-29 | Code: H | nature_of_ownership: By Decheng Capital Global Healthcare Fund (Master), LP | shares_owned_after: 891,734.00 | Footnotes: F6

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
• F6: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.